These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33146911)

  • 1. Quality Control Testing, Characterization and Critical Quality Attributes of Adeno-Associated Virus Vectors Used for Human Gene Therapy.
    Wright JF
    Biotechnol J; 2021 Jan; 16(1):e2000022. PubMed ID: 33146911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in scaling up AAV-based gene therapy manufacturing.
    Jiang Z; Dalby PA
    Trends Biotechnol; 2023 Oct; 41(10):1268-1281. PubMed ID: 37127491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of quality attributes for adeno-associated viral vectors.
    Tustian AD; Bak H
    Biotechnol Bioeng; 2021 Nov; 118(11):4186-4203. PubMed ID: 34309017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of the quality by design approach for gene therapy products: A case study for adeno-associated viral vectors.
    Tanaka T; Hanaoka H; Sakurai S
    Eur J Pharm Biopharm; 2020 Oct; 155():88-102. PubMed ID: 32784043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manufacturing and characterizing AAV-based vectors for use in clinical studies.
    Wright JF
    Gene Ther; 2008 Jun; 15(11):840-8. PubMed ID: 18418418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example.
    De BP; Chen A; Salami CO; Van de Graaf B; Rosenberg JB; Pagovich OE; Sondhi D; Crystal RG; Kaminsky SM
    Hum Gene Ther Methods; 2018 Jun; 29(3):146-155. PubMed ID: 29706115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy.
    Balakrishnan B; Jayandharan GR
    Curr Gene Ther; 2014; 14(2):86-100. PubMed ID: 24588706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug product Formulation and Fill/Finish Manufacturing Process Considerations for AAV-Based Genomic Medicines.
    Som M; Gikanga B; Kanapuram V; Yadav S
    J Pharm Sci; 2024 Jul; 113(7):1711-1725. PubMed ID: 38570073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving from the bench towards a large scale, industrial platform process for adeno-associated viral vector purification.
    Adams B; Bak H; Tustian AD
    Biotechnol Bioeng; 2020 Oct; 117(10):3199-3211. PubMed ID: 32573761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
    Liu Y; Siriwon N; Rohrs JA; Wang P
    Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors.
    Srivastava A; Mallela KMG; Deorkar N; Brophy G
    J Pharm Sci; 2021 Jul; 110(7):2609-2624. PubMed ID: 33812887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rAAV vector product characterization and stability studies.
    Snyder RO; Audit M; Francis JD
    Methods Mol Biol; 2011; 807():405-28. PubMed ID: 22034040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel method for the quantification of adeno-associated virus vectors for RNA interference applications using quantitative polymerase chain reaction and purified genomic adeno-associated virus DNA as a standard.
    Wagner A; Röhrs V; Kedzierski R; Fechner H; Kurreck J
    Hum Gene Ther Methods; 2013 Dec; 24(6):355-63. PubMed ID: 23987130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors.
    El Andari J; Grimm D
    Biotechnol J; 2021 Jan; 16(1):e2000025. PubMed ID: 32975881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-associated virus vector as a platform for gene therapy delivery.
    Wang D; Tai PWL; Gao G
    Nat Rev Drug Discov; 2019 May; 18(5):358-378. PubMed ID: 30710128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
    Schön C; Biel M; Michalakis S
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus vectors and neurological gene therapy.
    Ojala DS; Amara DP; Schaffer DV
    Neuroscientist; 2015 Feb; 21(1):84-98. PubMed ID: 24557878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the Quality of Adeno-Associated Viral Vector Preparations: The Challenge of Product-Related Impurities.
    Schnödt M; Büning H
    Hum Gene Ther Methods; 2017 Jun; 28(3):101-108. PubMed ID: 28322595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vector characterization methods for quality control testing of recombinant adeno-associated viruses.
    Wright JF; Zelenaia O
    Methods Mol Biol; 2011; 737():247-78. PubMed ID: 21590401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors.
    Burnham B; Nass S; Kong E; Mattingly M; Woodcock D; Song A; Wadsworth S; Cheng SH; Scaria A; O'Riordan CR
    Hum Gene Ther Methods; 2015 Dec; 26(6):228-42. PubMed ID: 26414997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.